Intensive Chemotherapy May Be Harmful to Most Older Patients With Acute Myeloid Leukemia
WASHINGTON, July 28 /PRNewswire-USNewswire/ -- The prognosis for nearly three-quarters of elderly patients on intensive chemotherapy for acute myeloid leukemia (AML) is poor, with a median survival of less than six months, according to a study published online today in Blood, the journal of the American Society of Hematology. AML is the most common form of acute leukemia among adults and is a rapidly...
Synta Announces STA-9090 Results Published in Journal “Blood” Demonstrating Potent In Vitro and In Vivo Activity in AML
– STA-9090 inhibits WT1, a key driver of leukemias –
– STA-9090 enhances activity of chemotherapy in leukemia cells –
– STA-9090 currently being studied in two AML clinical trials –
Patients in the UK with myelodysplastic syndromes will be celebrating news that the National Institute for Health and Clinical Excellence has been ordered to reassess Celgene’s Vidaza for the National Health Service.
An Appeal Board has agreed with certain objections voiced in appeals by Celgene and a whole host of other bodies - including Royal Colleges and support group MDS UK - against a ruling by the cost watchdog...
CytRx’s Tamibarotene Eradicates Cancer in Advanced Acute Promyelocytic Leukemia After Failure of Other Therapies
Tamibarotene-Treated Leukemia Patient Achieves Molecular Complete Remission Following Relapses After Receiving First- and Second-Line Treatments and a Bone Marrow Transplant
Patient Report Published in the July Peer-Reviewed British Journal of Haematology
SOUTH SAN FRANCISCO, CA--(Marketwire - July 15, 2010) - Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the European Patent Office (EPO) has granted a European patent covering combinations of the Company's lead drug candidate, voreloxin, with cytarabine. Cytarabine is the standard-of-care treatment for Acute Myeloid Leukemia (AML), and the therapy used in combination with voreloxin in a fully...
Blog Categories
Uncategorized
(5)
